Handelsavisen
prelaunch
Companies ›Healthcare ›CAND.NS
CA
CAND.NS — NSE (India) Healthcare Facilities & Services

Cand.Ns

$246,85
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
15,6 %
ROE
18,1 %
Net margin
9,6 %
Debt / equity
0,39
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

CAND.NS operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medicines and related healthcare solutions.

Business. CAND.NS operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medicines and related healthcare solutions.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
18,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CAND.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CAND.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CAND.NS operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of medicines and related healthcare solutions.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    CAND.NS has a debt-to-equity ratio of 0.39, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.94, suggesting it can cover its short-term obligations but with limited excess capacity.

    In terms of profitability, CAND.NS reports a return on equity (ROE) of 18.08% and a return on assets (ROA) of 10.53%. These figures are strong and suggest the company is effectively utilizing its equity and assets to generate returns, outperforming the typical benchmarks for the healthcare industry.

    The company's revenue is primarily concentrated in its core pharmaceutical operations, with no significant geographic diversification disclosed. This concentration may expose the company to regional economic fluctuations and regulatory changes, which could impact its revenue stability.

    CAND.NS has demonstrated a growth trajectory, with a revenue of INR 2.3 billion in the latest reporting period. However, the company's operating cash flow is negative at INR -290.5 million, and free cash flow is also negative at INR -114.4 million, indicating potential challenges in generating sufficient cash from operations to support its capital expenditures and debt obligations.

    The risk assessment for CAND.NS highlights a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure from dilutive events such as share buybacks or new issuances. The company's capital expenditures of INR -387.05 million suggest ongoing investment in infrastructure and operations, which could impact short-term liquidity.

    Recent events and filings indicate that CAND.NS has not disclosed any major strategic shifts or regulatory challenges in the latest reporting period. The company's financial health appears stable, but the negative cash flow metrics suggest a need for careful monitoring of its liquidity and capital structure.

    Key takeaways
    • CAND.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.39.
    • The company's ROE of 18.08% and ROA of 10.53% indicate strong profitability and efficient asset utilization.
    • Revenue is concentrated in core pharmaceutical operations, with no significant geographic diversification.
    • Negative operating and free cash flows suggest potential liquidity challenges.
    • The company's liquidity risk is medium, and dilution risk is low.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $246,85
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $1.23B
    Net cashⓘ
    -$481.6M
    Current ratioⓘ
    1.9
    Debt / equityⓘ
    0.4
    ROAⓘ
    10.5%
    ROEⓘ
    18.1%
    Cash conversionⓘ
    -131.0%
    CapEx / revenueⓘ
    -16.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin15,6 %Above median
    Net Margin9,6 %Above median
    ROE18,1 %Above P75
    Capex / Rev-16,8 %Bottom quartile
    D/E0,39Above median
    Cash Conv-1,31Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • CAND.NS Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Amar SinghManaging Director (Promoter)
    • Asmita SinghManaging Director (Promoter)

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CAND.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage